Skip to main content
SpringerLink
Log in

Regulation of BAX and BCL‐2 expression in breast cancer cells by chemotherapy

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Optimizing chemotherapeutic drug delivery strategies relies, in part, on identification of the most clinically effective sequence, dose, and duration of drug exposure. The combination of dose intensive etoposide (VP‐16) followed by cyclophosphamide has clinical efficacy in the treatment of advanced breast cancer. However, molecular mechanisms that underlie the effectiveness of this combination of chemotherapeutic agents have not been investigated. In this study we investigated regulation of BAX and BCL‐2 expression by VP‐16 and cyclophosphamide as a potential mechanism for the induction of breast cancer cell death induced by this regimen.

There was a dose and time dependent increase in BAX expression in the breast cancer cell lines MCF‐7, MDA‐MB‐435S, and MDA‐MB‐A231 following in vitro treatment with 50–100 μM VP‐16. Elevation of BAX protein expression in the presence of VP‐16 alone did not correlate with reduced viability or induction of apoptosis in MCF‐7, MDA‐MB‐435S, or MDA‐MB‐A231. VP‐16 did effectively block the breast cancer cell lines evaluated (MCF‐7 and MDA‐MB‐435S) at G2/M phase of the cell cycle, confirming activity of the drug in vitro. MCF‐7 and MDA‐MB‐435S cells that were pre‐treated with VP‐16 and subsequently exposed to 1.0–12.0 μg/m1 4‐hydroperoxycyclophosphamide (4HC), an active metabolite of cyclophosphamide, had markedly reduced viability when compared to matched controls treated with either VP‐16 or 4HC individually. Consistent with this loss of viability, exposure of all three cell lines to the combination of VP‐16 and 4HC resulted in higher BAX protein levels than those observed following treatment with either single agent. This combination of chemotherapeutic agents also resulted in reduced BCL‐2 expression.

These observations suggest that combination chemotherapy may derive its efficacy, in part, through coordinated regulation of specific gene products associated with apoptosis. Characterization of molecular events that underlie susceptibility of specific tumor cells to combination chemotherapeutic regimens may lead to additional improvements in treatment strategies for this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Harden EA, Hande KR, Herzig GP: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473–479, 1990

    Google Scholar 

  2. Herzig RH, Lynch J, Christiansen NP, Fay JW, Davis MP, Herzing GP: Dose-intensive chemotherapy with etoposidecylophosphamide for advanced breast cancer. Semin Oncol 23: 28–32, 1996

    Google Scholar 

  3. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, and other anti-cancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353–2362, 1990

    Google Scholar 

  4. Yamada T, Chyma H: Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int J Radiat Biol 53: 64–78, 1988

    Google Scholar 

  5. Alan DJ: Radiation-induced apoptosis: Its role in a MADCAT (mitosis-apoptosis differentiation-calcium toxicity) scheme of cytotoxicity mechanisms. Int J Radiat Biol 62: 145–152, 1992

    Google Scholar 

  6. Wyllie AH, Kerr JK, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68: 251–305, 1980

    Google Scholar 

  7. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456–1462, 1958.

    Google Scholar 

  8. Tsujimoto Y, Gorham J, Cossman J, Jaffe B, Croce CM: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390–1393, 1985

    Google Scholar 

  9. Simonian PL, Grillot DAM, Nunez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208–1216, 1997

    Google Scholar 

  10. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994

    Google Scholar 

  11. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539–542, 1994

    Google Scholar 

  12. Chen M, Quintans J, Fuks Z, Thompson C, Kufe DW, Weichselbaum RR: Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α, and ceramide. Cancer Research 55: 991–994, 1995

    Google Scholar 

  13. Simonian PL, Grillot DAM, Merino R, Nunez G: Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. J Biol Chem 37: 22764–22772, 1996

    Google Scholar 

  14. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagner C, Kallinich B, Royer HD, Doerken B: Expression of the Bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854–859, 1995

    Google Scholar 

  15. Chouhei S, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T: Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67: 101–105, 1996

    Google Scholar 

  16. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Geller A, Royer HD, Dorken B: Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 97: 2652–2659, 1996

    Google Scholar 

  17. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dorken B: Induction of the death-promoting gene Bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67: 138–141, 1996

    Google Scholar 

  18. Eastman A: Activation of programmed cell death by anti-cancer agents: Cisplatin as a model system. Cancer Cells 2: 275–280, 1990

    Google Scholar 

  19. Patel R, Twigg J, Crossley I, Golsteyn R, Whitaker M: Calcium-induced chromatin condensation and cyclin phosphorylation during chromatin condensation cycles in ammonia-activated sea urchin eggs. J Cell Sci S12: 129–144, 1989

    Google Scholar 

  20. Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507–4511, 1995

    Google Scholar 

  21. Ogretmen B, Safa AR: Down-regulation of apoptosis-related bcl-2 but not bcl-XL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608–614, 1996

    Google Scholar 

  22. Fattman CL, An B, Sussman L, Dou QP: p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Lett 130: 103–113, 1998

    Google Scholar 

  23. Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD: Mitoguazone induces apoptosis via a p53-independent mechanism. Anti-cancer Drugs 9: 635–40, 1998

    Google Scholar 

  24. Gibson LF, Fortney J, Piktel D, Landreth KS, Lynch JP: Disruption of bone marrow stromal cell function by etoposide. Biology of Blood and Marrow Transplantation 3: 122–132, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, West Virginia University, Morgantown, West Virginia, USA

    Laura F. Gibson, James Fortney, Gabrielle Magro & Kenneth S. Landreth

  2. Department of Microbiology and Immunology, West Virginia University, Morgantown, West Virginia, USA

    Laura F. Gibson, Solveig G. Ericson & Kenneth S. Landreth

  3. Department of Medicine, West Virginia University, Morgantown, West Virginia, USA

    Solveig G. Ericson & Joseph P. Lynch

  4. Department of Blood and Marrow Transplantation Program of the Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, USA

    Laura F. Gibson, Solveig G. Ericson, Joseph P. Lynch & Kenneth S. Landreth

Authors
  1. Laura F. Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Fortney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gabrielle Magro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Solveig G. Ericson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph P. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth S. Landreth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibson, L.F., Fortney, J., Magro, G. et al. Regulation of BAX and BCL‐2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat 55, 107–117 (1999). https://doi.org/10.1023/A:1006175811676

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006175811676

Search

Navigation